Clinical Trials Logo

Clinical Trial Summary

This is a phase I/II-trial with D,L-methadone and mFOLFOX6 in the treatment of patients with histologically confirmed chemo-refractory colorectal carcinoma. The aim of the phase-I trial is to evaluate the toxicity-profile and the dose-limiting toxicity of D,L-methadone combined with mFOLFOX6. Furthermore, to estimate the maximum tolerated dose and the recommended dose for phase-II-trial in the treatment of patients with histologically confirmed colorectal carcinoma not amenable to or progressing while having received all standard therapies. The primary endpoint of the randomized phase-II study is to determine the disease control rate 12 weeks after randomization of patients with histologically confirmed advanced colorectal carcinoma upon treatment with D,L methadone plus mFOLFOX6 versus mFOLFOX6 alone. Overall response rate according to RECIST1.1, progression free survival (PFS), overall survival (OS), quality of life (QoL) according to the EORTC QLQc30 questionnaire, patient-reported outcomes and safety will be evaluated as secondary objectives.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05212012
Study type Interventional
Source AIO-Studien-gGmbH
Contact AIO-Studien-gGmbH
Phone +49308145344
Email [email protected]
Status Recruiting
Phase Phase 1/Phase 2
Start date February 17, 2022
Completion date June 15, 2025